ABSTRACT Objective: Talinum paniculatum (Jacq.) Gertn (T. paniculatum), is extensively used in Asian traditional medicine as a reproductive tonic. However, there is no conclusive scientific data to support this practice. This study was conducted to explore the possible estrogenic activity of T. paniculatum extracts compared with 17ß-estradiol (E2) in adult bilaterally ovariectomized (OVX) rats for the experimental model of menopause.
Methods: OVX female Wistar rats were randomly divided into six groups. The first group was orally treated with sesame oil as a vehicle control. The other six groups were treated with different treatments consisted of the groups which were treated by a positive standard control of 17ß-estradiol (10μg. kg-1BW), T. paniculatum root or leaf extract at two different doses (100 and 1,000 for 42 consecutive days, respectively. Estrogenic activity was evaluated by determining the vaginal cornification, relative uterine weight (%RU), relative mammary weight (%RM), and their histoarchitecture changes.
Results: T. paniculatum root and leaf extracts significantly increased the vaginal cornification (P<0.001). Compared to OVX control, a dose dependency response of %RU, %RM and proliferative changes in vagina, uterus and mammary ductular tissue were significantly observed in OVX treated with all dosages of T. paniculatum from root and leaf extracts (P<0.05).
Conclusion: T. paniculatum extracts possess estrogenic activity in the OVX rats, which can be helpful in managing reproductive tissues regression during menopause in a natural way through herbal resources without any toxicity.

Download full-text


Available from: Catthareeya Sukwan, Sep 29, 2015
285 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Numerous symptoms can be attributed to the lack of oestrogen at the time of the menopause. Some of the mechanisms for this are still unclear. However, while there is substantial evidence that many of the symptoms that women encounter during the menopausal period can be directly attributed to oestrogen deficiency, others are less well supported. An up-to-date review of the literature is provided.
    Best practice & research. Clinical obstetrics & gynaecology 02/2009; 23(1):25-32. DOI:10.1016/j.bpobgyn.2008.10.002 · 1.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effect of a soy-rich diet on urogenital symptoms, vaginal health index, and vaginal cytology in perimenopausal and postmenopausal women. Thirty-six perimenopausal and postmenopausal women (mean age 52.5+/-5.1 years) participated in a randomized, cross-over trial with two 12-week diet periods and two 4-week washout periods before and between treatments. The study diet consisted of a control diet (soy-free diet) and an isocaloric soy-rich diet (25 g soy protein in various forms of soy food containing more than 50 mg/day of isoflavones substituted for an equivalent amount of animal protein). Subjects were assessed for urogenital symptoms, vaginal health index, vaginal pH and vaginal cytology. The single physician and the single cytopathologist were blinded with regard to onset, period and randomization number. Statistical analyses were performed using paired t-test or Wilcoxon Signed Ranks Test, significance was set as P<0.05. Good compliance to the diet was shown by the significant elevation of serum levels of daidzein and genistein during the soy-rich diet period. The symptoms of urge incontinence and vaginal dryness had significantly increased after 12-week of soy-free diet. All other urogenital symptoms did not change in both periods. The vaginal health index, the vaginal pH, the karyopyknotic index, and the maturation value were not significantly changed in both periods. A soy-rich diet did not relieve the urogenital symptoms or restore the vaginal epithelium or improve the vaginal health in perimenopausal and postmenopausal Thai women.
    Maturitas 05/2006; 54(2):135-40. DOI:10.1016/j.maturitas.2005.09.011 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite a re-evaluation of risks in recent years, hormone replacement therapy is still surrounded by controversy. Almost 30% of women in a recent survey sought a natural approach to combat climacteric symptoms. Nevertheless, a large proportion of patients felt that they wanted a good safety profile and strong evidence base for treatment. This article seeks to review the evidence supporting non-hormonal approaches to treatment. There is only conflicting evidence at best to support alpha-2 agonists, e.g. clonidine and limited evidence for dihydroepiandrosterone and natural progesterones. There is limited randomized controlled trial data for gabapentin, selective norepinephrine re-uptake inhibitors (SNRIs) and selective serotonin re-uptake inhibitors (SSRIs), many of these studies being related to breast cancer patients. Of the herbal medicinal products, the largest evidence base rests with phytoestrogens. A Cochrane Database review looking at all types of phytoestrogens, e.g. red clover extracts, dietary soya and soya extracts concluded that there was no evidence to support improvement in climacteric symptoms and the meta-analysis of a 178 studies on soy products was inconsistent. Nevertheless, other studies disagree. Mammographic density is not affected by soy or phytoestrogen products and recent in vitro work shows only a weakly proliferative effect of soy isoflavone on breast cancer cells and evidence that soy isoflavone blocks the proliferative effect of estradiol on these cells. There are no studies looking at clinical outcome measures for cardiovascular disease but a number of studies looking at biochemical markers including arterial wall stiffness and apolipo protein B. Recent studies have also looked at the effects of red clover isoflavone on mood and depression, using specific depression rating scales. Finally, it is important to note that herbal medicinal products should not be used without caution. Some may produce quite marked side-effects in high doses and others can interact with pre-existing medication. A strategy for which patients are suitable for herbal medicinal products is reviewed.
    Menopause International 03/2012; 18(1):20-7. DOI:10.1258/mi.2012.012001
Show more